Company Filing History:
3 out of 12 
2 out of 4 
1 out of 2 Years Active: 2014-2019
Title: Caroline Breitbach: Innovator in Tumor Immunotherapy
Introduction
Caroline Breitbach is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of tumor immunotherapy, holding a total of 4 patents. Her work focuses on innovative methods to enhance the immune response against tumors, particularly through the use of oncolytic viruses.
Latest Patents
Among her latest patents is the invention related to the generation of antibodies to tumor antigens and the induction of tumor-specific complement-dependent cytotoxicity by administering oncolytic vaccinia virus. This invention outlines methods and compositions designed to induce a tumor-specific antibody-mediated complement-dependent cytotoxic response in animals with tumors. The administration of a replication-competent oncolytic virus leads to the production of antibodies that specifically target the tumor, enhancing the immune response.
Career Highlights
Caroline has worked with notable companies in the biotherapeutics sector, including Sillajen Biotherapeutics, Inc. and Sillajen, Inc. Her expertise in the field has positioned her as a key player in the development of innovative cancer therapies.
Collaborations
Throughout her career, Caroline has collaborated with esteemed colleagues such as David H. Kirn and John Cameron Bell. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Caroline Breitbach's work in tumor immunotherapy exemplifies the impact of innovative thinking in the medical field. Her patents and collaborations highlight her commitment to advancing cancer treatment through scientific research and development.